NAD+

NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme essential for cellular energy metabolism, DNA repair, and sirtuin activation. It is not a peptide — NAD+ is a small dinucleotide molecule composed of a nicotinamide group, an adenine group, and two phosphate groups connected by ribose sugars. It is covered on this peptide platform only because vendors commonly sell injectable NAD+ alongside research peptides, and buyers verify it the same way — so it is reviewed here, but it is not a peptide and is not evaluated as one. It is grouped with peptides in research-chemical catalogs due to overlapping research interest in longevity, mitochondrial function, and metabolic health. NAD+ is not approved as a therapeutic for the longevity indication, but the related compound NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide) are sold as dietary supplements in most jurisdictions.

What is NAD+ and how does the cellular energy/sirtuin mechanism work?

NAD+ is the oxidized form of nicotinamide adenine dinucleotide, a coenzyme that participates in hundreds of cellular redox reactions including ATP production, DNA repair via PARP enzymes, and gene expression regulation via sirtuin (SIRT1-7) deacetylases. Endogenous NAD+ levels decline with age, and the hypothesis driving longevity research is that restoring NAD+ levels supports cellular function decline associated with aging. NAD+ itself has poor oral bioavailability, leading to research interest in precursor compounds (nicotinamide riboside, NMN) and direct administration approaches.

Evidence level: established biochemistry (cellular function); preclinical (longevity); limited human clinical for direct NAD+ administration

What does the research show for NAD+?

Preclinical rodent studies have reported improvements in mitochondrial function, vascular health, and lifespan extension with NAD+ precursor supplementation. Human observational studies suggest correlation between NAD+ levels and age-related decline markers. Direct NAD+ administration (intravenous or subcutaneous) has limited published clinical data. The most-studied route to raising NAD+ in humans is oral precursor supplementation (nicotinamide riboside, NMN). These precursors reliably increase blood NAD+ levels, but randomized controlled trials have not translated that into established functional or clinical benefit: a 2025 systematic review and meta-analysis of 10 RCTs in older adults concluded that current evidence does not support NR or NMN for preserving muscle mass, strength, or physical performance. Raising a molecule's level is not the same as improving an outcome, and for NAD+ that gap is not yet closed. Robust human RCT evidence for direct NAD+ as a longevity intervention is not yet available.

Source: The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis, Prokopidis K., Moriarty F., Bahat G., McLean J., Church D.D., Patel H.P., Journal of Cachexia, Sarcopenia and Muscle, 2025 · Evidence level: preclinical (longevity, mitochondrial); human observational and trials for precursors; direct NAD+ administration: limited human RCT

How does NAD+ compare to other longevity-targeted compounds?

NAD+ operates on a fundamental biochemistry pathway (cellular energy and sirtuin activation) with extensive mechanistic support — contrasting with proposed-mechanism compounds like Khavinson bioregulators. Among longevity-targeted research compounds, NAD+ has the most well-characterized basic biochemistry.

What are the documented side effects of NAD+?

Direct NAD+ administration (intravenous or subcutaneous) commonly produces transient side effects including flushing, headache, gastrointestinal upset, and mild blood pressure changes — particularly during infusion at higher doses. Long-term safety of sustained direct NAD+ administration is not well-characterized in human RCT data. Oral NAD+ precursors (NR, NMN) have a more favorable side-effect profile.

Evidence level: clinical observation of acute effects; long-term safety unestablished for direct administration

What is the regulatory status of NAD+?

NAD+ is not approved as a therapeutic for longevity, aging, or related indications anywhere in the world as of August 2026. It is widely available as a dietary supplement in precursor forms (NR, NMN) in most jurisdictions. Direct NAD+ administration is offered through IV clinics in some markets — that practice is generally legal as medical service but not FDA-evaluated for safety or efficacy claims. Regulatory context in are peptides legal regulatory status by country.

Why does NAD+ vendor verification matter for a dinucleotide?

NAD+ is a small dinucleotide molecule, not a peptide, so identity verification stack differs — HPLC and mass spectrometry remain relevant but with different reference standards and impurity profiles than peptides. Some vendors substitute related nucleotides (NADH, NMN, NR) labeled as NAD+. Independent third-party testing is essential. The peptide-specific guidance in how-to-test-peptides hub does not all directly apply.

How does Peptigrity verify NAD+ vendors?

Peptigrity collects independent third-party Certificates of Analysis for NAD+ from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. Methodology in how we calculate trust scores.

Frequently asked questions

Is NAD+ a peptide?

No. NAD+ is a small dinucleotide molecule, not a peptide. It is grouped with peptides in research-chemical catalogs because of overlapping research interest in longevity and metabolic health.

What's the difference between NAD+ and NMN or NR?

NAD+ is the active coenzyme directly; NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors that the body converts to NAD+. Oral NMN and NR are widely sold as dietary supplements; direct NAD+ administration is typically via IV or subcutaneous injection because oral NAD+ has poor bioavailability.

Is NAD+ legal to purchase?

NAD+ is legal to purchase as a research chemical for laboratory use in most jurisdictions. Oral NAD+ precursors (NR, NMN) are sold as dietary supplements in most markets. Direct NAD+ administration through IV clinics operates as medical service in many jurisdictions. Country breakdown in peptide legal status guide.

Is NAD+ a longevity treatment?

There is no FDA-approved longevity treatment, and NAD+ specifically is not approved for any longevity, anti-aging, or aging-related indication. Preclinical evidence for NAD+ pathway support in age-related decline is substantial, but human RCT evidence at FDA-grade standards is more limited — particularly for direct NAD+ administration versus precursor supplementation.

How can I verify an NAD+ vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation appropriate to dinucleotides. Mislabeling with related nucleotides (NADH, NMN, NR) occurs. COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend an NAD+ dose?

No. Peptigrity is an independent review platform, not a medical authority. IV clinic protocols for NAD+ vary widely. Anyone considering NAD+ use should consult a licensed physician.

This section is for educational and informational purposes only and does not constitute medical advice. NAD+ is not approved as a therapeutic for longevity or aging indications. Always consult a qualified healthcare provider before using any compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.